BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen

(TheNewswire)

VANCOUVER, British Columbia – TheNewswire - December 4, 2025 -BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE:BETR / OTCQB:BETRF / FRA: NPAU ) ,an emerging biotech company, focused on development of BETR-001, itsproprietary non-hallucinogenic derivative of lysergic aciddiethylamide (“LSD”).

Following recent news from a Phase 2 trial showing LSDmicrodosing is ineffective for depression, BetterLife highlightsBETR-001's advantages over LSD. BETR-001 remainsnon-hallucinogenic even at high doses, as shown in our previous pu blication ,and does not induce tolerance with repeated use, meaning that BETR-001can be dosed on a chronic or repeated basis. Preclinical studiesindicate that neuroplastogenic effects require sufficient dosing.Since BETR-001 can be administered at full dose withouthallucinations, it maintains its effectiveness following repeateddosing.

Dr. Ahmad Doroudian, CEO of BetterLife, commented,“The importance of being able to give full doses of BETR-001 withouthallucinations cannot be over-emphasized. Microdosing of psychedelicsis often touted as the path forward to avoid the hallucinations ofpsychedelics full dosing and the need for treatment in specializedclinics with monitoring under special treatment protocols, whichrequire in-clinic time of 8 to 12 hours. BETR-001 overcomes all thesehurdles and can be administered at its full effective dose without anyhallucinations.”

Dr. Doroudian further commented, “We are completingthe last remaining BETR-001 IND-enabliing studies and plan to file theIND and begin human clinical trials by 2H 2026. Our initial scope isto develop BETR-001 for treatment of Traumatic Brain Injury(“TBI”), cluster headaches and migraine. BETR-001 also haspotential for treatment of a broad range of psychiatric disorders andthey will also be explored as the compound’s development life cyclemoves forward.”

About BetterLife Pharma

BetterLife Pharma Inc.is an emerging biotechnology company primarily focused on developingand commercializing BETR-001 to treat various neurological disorders.BETR-001, which is in preclinical and IND-enabling studies, is anon-hallucinogenic and non-controlled LSD derivative in developmentand it is unique in that it is unregulated and therefore can beself-administered. BetterLife’s synthesis patent for BETR-001eliminates regulatory hurdles and its pending patent, for compositionand method of use, covers treatment of various neurological disorders,until around 2042.

BetterLife also owns a drug candidate for the treatmentof viral infections and is in the process of seeking strategicalternatives for further development.

For further information, please visit BetterLifePharma .

Contact

Ahmad Doroudian, Chief Executive Officer

Email: Ahmad.Doroudian@blifepharma.com

Phone: 1-604-221-0595

Cautionary Note RegardingForward-Looking Statements

No securities exchange has reviewed nor acceptsresponsibility for the adequacy or accuracy of the content of thisnews release. This news release contains forward-looking statementsrelating to product development, licensing, commercialization andregulatory compliance issues and other statements that are nothistorical facts. Forward-looking statements are often identified byterms such as “will”, “may”, “should”, “anticipate”,“expects” and similar expressions. All statements other thanstatements of historical fact, included in this release areforward-looking statements that involve risks and uncertainties. Therecan be no assurance that such statements will prove to be accurate andactual results and future events could differ materially from thoseanticipated in such statements. Important factors that could causeactual results to differ materially from the Company’s expectationsinclude the failure to satisfy the conditions of the relevantsecurities exchange(s) and other risks detailed from time to time inthe filings made by the Company with securities regulations. Thereader is cautioned that assumptions used in the preparation of anyforward-looking information may prove to be incorrect. Events orcircumstances may cause actual results to differ materially from thosepredicted, as a result of numerous known and unknown risks,uncertainties, and other factors, many of which are beyond the controlof the Company. The reader is cautioned not to place undue reliance onany forward-looking information. Such information, although consideredreasonable by management at the time of preparation, may prove to beincorrect and actual results may differ materially from thoseanticipated. Forward-looking statements contained in this news releaseare expressly qualified by this cautionary statement. Theforward-looking statements contained in this news release are made asof the date of this news release and the Company will update or revisepublicly any of the included forward-looking statements as expresslyrequired by applicable law.

Copyright (c) 2025 TheNewswire - All rights reserved.